APA (7th ed.) Citation

Reshetnyak, T. M., Aseeva, E. A., Shumilova, A. A., Nikishina, N. Y., Glukhova, S. I., Shkireeva, S. Y., & Lila, A. M. (2024). Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study). IMA-PRESS LLC.

Chicago Style (17th ed.) Citation

Reshetnyak, T. M., E. A. Aseeva, A. A. Shumilova, N.  Yu Nikishina, S. I. Glukhova, S. Yu Shkireeva, and A. M. Lila. Efficacy and Safety of the Type I Interferon Receptor Inhibitor Anifrolumab in Patients with Systemic Lupus Erythematosus (results of a 6-month Study). IMA-PRESS LLC, 2024.

MLA (9th ed.) Citation

Reshetnyak, T. M., et al. Efficacy and Safety of the Type I Interferon Receptor Inhibitor Anifrolumab in Patients with Systemic Lupus Erythematosus (results of a 6-month Study). IMA-PRESS LLC, 2024.